Update on MESSINA Phase III trial
25 October 2022 07:00 BST Update on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis MESSINA did not meet one of the two dual-primary endpoints, demonstrating a statistically significant improvement in histological disease remission with Fasenra, but not in dysphagia symptoms, compared to placebo Eosinophilic esophagitis (EoE) is a rare, progressive, chronic inflammatory disease of the esophagus currently believed to be characterised by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus.[1-3] Patients experience